Analysts Trim Targets as Pfizer Approaches Q2 Print

Pfizer heads into its July 28 earnings report with the Street in a quiet retreat — analysts cutting targets but holding ratings, while positioning data shows no particular stress in either direction.

The most telling pre-earnings signal is the drift in analyst targets. Several firms trimmed price objectives in the two weeks before the print without changing their ratings: JPMorgan cut to $28 from $30 while holding Neutral, BofA lowered to $26 from $27 also at Neutral, and BMO Capital — one of the more constructive voices — sliced its Outperform target to $30 from $34. The outlier was HSBC, which went further with an outright downgrade to Hold from Buy, cutting its target to $28 from $32. The consensus mean now sits around $28.75, implying roughly 17% upside from the current $24.54 — meaningful headroom on paper, but the direction of travel is clearly lower. None of these moves changed ratings from positive to negative; they reflect a Street that still believes in the name but is becoming more cautious on near-term execution.

Bulls point to the long-term value case: a forward EPS estimate that implies a dramatic earnings recovery from a depressed post-pandemic base, a PE running near 8.7x, an EV/EBITDA around 8.2x, and a dividend yield close to 7% — all metrics that rank PFE attractively on value screens. The bear case is less about the balance sheet and more about revenue quality: anticipated gross-to-net adjustments on premium drugs like Vyndaqel and Ibrance could pressure reported numbers, and the market has shown limited patience for guidance misses. The factor score on 12-month forward EPS growth ranks in the 96th percentile, but 30-day and 90-day EPS momentum both trail, suggesting the recovery story is real but unevenly timed.

Short positioning offers little drama heading in. SI runs at just 2.7% of free float — low by any measure — and while it ticked up roughly 6% on the week to around 156 million shares, that follows a month where shorts were actively covering. Borrow availability is extraordinarily loose at over 4,200%, meaning there are far more shares available to lend than are currently borrowed. Cost to borrow, though up about 22% on the week, remains negligible at 0.52%. Options pricing is similarly calm: the put/call ratio of 0.84 is running almost exactly in line with its 20-day average, with a z-score near zero — no rush to buy downside protection ahead of the release. The stock has slipped about 2% on the week and just under 1% over the past month, drifting rather than breaking.

The print will therefore test whether Pfizer's value credentials — cheap multiples, high yield, and a forward earnings recovery that analysts broadly still endorse — are enough to arrest the quiet erosion in both price and Street conviction.